POSC166 Cost-Effectiveness of Emicizumab Prophylaxis Therapy Versus Recombinant Activated FVII On-Demand Therapy for Hemophilia A with Inhibitors in China

Abstract

Authors

Z Lin X Ran C Liu J Xuan

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×